Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 11/20 | 0.69 |
| ▸ | CA2 | P00918 | 11/20 | 0.69 |
| ▸ | CA9 | Q16790 | 7/20 | 0.69 |
| ▸ | CA4 | P22748 | 6/20 | 0.69 |
| ▸ | CA12 | O43570 | 2/20 | 0.69 |
| ▸ | CA3 | P07451 | 2/20 | 0.69 |
| ▸ | CA6 | P23280 | 2/20 | 0.69 |
| ▸ | CA5A | P35218 | 2/20 | 0.69 |
| ▸ | CA7 | P43166 | 2/20 | 0.69 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.69 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.69 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.69 |
| ▸ | MEN1 | O00255 | 3/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | CA11 | O75493 | 1/20 | 0.62 |
| ▸ | THRB | P10828 | 1/20 | 0.62 |
| ▸ | BLM | P54132 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11821585 | 0.85 | CA1 (0.54) | CA1CA2CA9CA4CA12 | |
| SCHEMBL10797173 | 0.82 | CA1 (1.00) | CA1CA2CA9CA4CA12 | |
| SCHEMBL11930741 | 0.82 | CA1 (0.76) | CA1CA2CA9CA4CA12 | |
| SCHEMBL18100211 | 0.78 | CA1 (0.72) | CA1CA2CA9CA4CA12 | |
| SCHEMBL11929008 | 0.78 | CA1 (0.69) | CA1CA2CA9CA4CA12 | |
| SCHEMBL13711902 | 0.78 | CA1 (0.69) | CA1CA2CA9CA4CA12 | |
| SCHEMBL629408 | 0.77 | CA1 (0.62) | CA1CA2CA9CA4CA12 | |
| SCHEMBL18656466 | 0.77 | CA1 (0.68) | CA1CA2CA9CA4CA12 | |
| Acetazolamide SCHEMBL2557036 | 0.77 | CA1 (1.00) | CA1CA2CA9CA4CA12 | |
| Acetazolamide SCHEMBL23219 | 0.77 | CA1 (1.00) | CA1CA2CA9CA4CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230058971-A1 | EXTENDED RELEASE MICROPARTICLES AND SUSPENSIONS THEREOF FOR MEDICAL THERAPY | Graybug Vision, Inc. (US) | 2023-02-23 | — | — | US | disclosed |
| US-20230056284-A1 | EXTENDED RELEASE MICROPARTICLES AND SUSPENSIONS THEREOF FOR MEDICAL THERAPY | Graybug Vision, Inc. (US) | 2023-02-23 | — | — | US | disclosed |
| US-11548861-B2 | Drugs and compositions for the treatment of ocular disorders | Graybug Vision, Inc. (US) | 2023-01-10 | — | — | US | disclosed |
| US-11160870-B2 | Extended release microparticles and suspensions thereof for medical therapy | Graybug Vision, Inc. (US) | 2021-11-02 | — | — | US | disclosed |
| US-20200230246-A1 | EXTENDED RELEASE MICROPARTICLES AND SUSPENSIONS THEREOF FOR MEDICAL THERAPY | Graybug Vision, Inc. (US) | 2020-07-23 | — | — | US | disclosed |
| US-20200031783-A1 | DRUGS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | Graybug Vision, Inc. (US) | 2020-01-30 | — | — | US | disclosed |
| US-9956302-B2 | Compounds and compositions for the treatment of ocular disorders | Graybug Vision, Inc. (US) | 2018-05-01 | — | — | US | disclosed |
| US-9956302-B2 | Compounds and compositions for the treatment of ocular disorders | Graybug Vision, Inc. (US) | 2018-05-01 | — | — | US | disclosed |
| US-20180110864-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | Graybug Vision, Inc. (US) | 2018-04-26 | — | — | US | disclosed |
| US-20180110864-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | Graybug Vision, Inc. (US) | 2018-04-26 | — | — | US | disclosed |
| US-20180028673-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | Graybug Vision, Inc. (US) | 2018-02-01 | — | — | US | disclosed |
| US-9808531-B2 | Compounds and compositions for the treatment of ocular disorders | Graybug Vision, Inc. (US) | 2017-11-07 | — | — | US | disclosed |
| US-9808531-B2 | Compounds and compositions for the treatment of ocular disorders | Graybug Vision, Inc. (US) | 2017-11-07 | — | — | US | disclosed |
| US-20170080092-A1 | Compounds And Compositions for the Treatment of Ocular Disorders | Graybug Vision, Inc. (US) | 2017-03-23 | — | — | US | disclosed |
| US-20170080092-A1 | Compounds And Compositions for the Treatment of Ocular Disorders | Graybug Vision, Inc. (US) | 2017-03-23 | — | — | US | disclosed |
| US-20100184033-A1 | METHODS TO ACCELERATE THE ISOLATION OF NOVEL CELL STRAINS FROM PLURIPOTENT STEM CELLS AND CELLS OBTAINED THEREBY | Lineage Cell Therapeutics, Inc. | 2010-07-22 | — | — | US | disclosed |
| US-20080226601-A1 | Herpes Virus-Based Compositions and Methods of Use in the Prenatal and Perinatal Periods | UNIVERSITY OF ROCHESTER (US) | 2008-09-18 | — | — | US | disclosed |
| EP-1903873-A2 | HERPES VIRUS-BASED COMPOSITIONS AND METHODS OF USE IN THE PRENATAL AND PERINATAL PERIODS | THE UNIVERSITY OF ROCHESTER (US) | 2008-04-02 | — | — | EP | disclosed |
| WO-2007062198-A1 | METHODS TO ACCELERATE THE ISOLATION OF NOVEL CELL STRAINS FROM PLURIPOTENT STEM CELLS AND CELLS OBTAINED THEREBY | ADVANCED CELL TECHNOLOGY, INC. (US) | 2007-05-31 | — | — | WO | disclosed |
| WO-2006135602-A2 | HERPES VIRUS-BASED COMPOSITIONS AND METHODS OF USE IN THE PRENATAL AND PERINATAL PERIODS | UNIVERSITY OF ROCHESTER (US) | 2006-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180028673-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | PTGIR, PTGIS, CA2 | CA1 149/4885CA2 3/4885CA9 51/4885 |
| US-20200031783-A1 | DRUGS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | PDE6C, PDE6A, PDE6D | CA1 3104/4885CA2 456/4885CA9 1255/4885 |
| US-11548861-B2 | Drugs and compositions for the treatment of ocular disorders | PDE6C, PDE6A, PDE6D | CA1 3104/4885CA2 456/4885CA9 1255/4885 |
| US-20170080092-A1 | Compounds And Compositions for the Treatment of Ocular Disorders | PTGIR, PTGIS, CA2 | CA1 149/4885CA2 3/4885CA9 51/4885 |
| US-11160870-B2 | Extended release microparticles and suspensions thereof for medical therapy | CHMP4B, EXOSC9, EXOSC5 | CA1 4689/4885CA2 3967/4885CA9 3773/4885 |
| US-20230058971-A1 | EXTENDED RELEASE MICROPARTICLES AND SUSPENSIONS THEREOF FOR MEDICAL THERAPY | CHMP4B, EXOSC9, EXOSC5 | CA1 4689/4885CA2 3967/4885CA9 3773/4885 |
| US-20200230246-A1 | EXTENDED RELEASE MICROPARTICLES AND SUSPENSIONS THEREOF FOR MEDICAL THERAPY | CHMP4B, EXOSC9, EXOSC5 | CA1 4689/4885CA2 3967/4885CA9 3773/4885 |
| US-20180110864-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | PTGIR, PTGIS, CA2 | CA1 149/4885CA2 3/4885CA9 51/4885 |
| US-20230056284-A1 | EXTENDED RELEASE MICROPARTICLES AND SUSPENSIONS THEREOF FOR MEDICAL THERAPY | CHMP4B, EXOSC9, EXOSC5 | CA1 4689/4885CA2 3967/4885CA9 3773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.